A family with a novel termination mutation in hepatic nuclear factor 1α in maturity-onset diabetes of the young type 3 which is unresponsive to sulphonylurea therapy

Horm Res Paediatr. 2014;81(4):280-4. doi: 10.1159/000356925. Epub 2014 Mar 12.

Abstract

Background: Maturity-onset diabetes of the young (MODY) is a monogenic form of diabetes mellitus.

Aims: To identify the genetic basis in a family with 3 generations of diabetes and to assess the concordance between the genotype and phenotype.

Methods: A molecular analysis was performed on genomic DNA using polymerase chain reaction, denaturing gradient gel electrophoresis, and sequencing. A mixed-meal tolerance test (MMTT) was performed with/without glibenclamide. Abdominal ultrasonography was performed on all family members with diabetes due to the location of the mutation.

Results: A novel c.618G>A, p.W206X termination mutation was identified in the hepatic nuclear factor 1α (HNF1α) gene. The mutation was identified in the proband and 8 of the 14 family members tested. An MMTT stimulus (±2.5 and 5 mg glibenclamide) produced a similar glucose profile and C-peptide graph in both the obese proband and her nonobese mother, showing no effect of the glibenclamide. No evidence of liver adenomas was found in the abdominal ultrasonography.

Conclusions: We described a novel c.618G>A, p.W206X mutation in HNF1α associated with MODY 3 but not with hepatocellular adenoma. In contradistinction to most MODY 3 mutations, treatment with sulphonylurea was found to be a clinically ineffective alternative to insulin therapy.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Child
  • Diabetes Mellitus, Type 2 / drug therapy
  • Diabetes Mellitus, Type 2 / genetics*
  • Female
  • Hepatocyte Nuclear Factor 1-alpha / genetics*
  • Humans
  • Hypoglycemic Agents / therapeutic use*
  • Insulin / therapeutic use*
  • Male
  • Middle Aged
  • Mutation*
  • Pedigree
  • Phenotype
  • Sulfonylurea Compounds / therapeutic use*
  • Treatment Outcome
  • Young Adult

Substances

  • HNF1A protein, human
  • Hepatocyte Nuclear Factor 1-alpha
  • Hypoglycemic Agents
  • Insulin
  • Sulfonylurea Compounds

Supplementary concepts

  • Maturity-Onset Diabetes of the Young, Type 3